Загрузка...
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
PURPOSE: This phase I study explored gefitinib (G) and capecitabine (C) in metastatic breast cancer (MBC). METHODS: Sequential cohorts (n=3) received G and escalating C on a 14 day on/7 day off schedule, with a validation cohort (n=10) at the maximum tolerated dose (MTD). Dose limiting toxicity (DLT...
Сохранить в:
| Опубликовано в: : | Breast Cancer Res Treat |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2009
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4578795/ https://ncbi.nlm.nih.gov/pubmed/19294501 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-009-0366-5 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|